Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.85 |
| ▸ | CRHBP | P24387 | 2/20 | 0.85 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.85 |
| ▸ | HTT | P42858 | 2/20 | 0.85 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.70 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.70 |
| ▸ | ITGAL | P20701 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL896371 | 1.00 | LMNA (0.85) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL35680 | 1.00 | LMNA (0.85) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL35510 | 1.00 | LMNA (0.85) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL288378 | 1.00 | LMNA (0.85) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL5030177 | 1.00 | LMNA (0.85) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL896445 | 1.00 | LMNA (0.85) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL35766 | 1.00 | LMNA (0.85) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL35802 | 1.00 | LMNA (0.85) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL15301625 | 1.00 | LMNA (0.85) | LMNASMN1; SMN2CRHBPCRHR2HTT | |
| SCHEMBL2167630 | 0.98 | LMNA (0.81) | LMNASMN1; SMN2CRHBPCRHR2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120107272-A1 | SYNTHETIC METHODS AND DERIVATIVES OF TRIPHOSPHATE OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8013136-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7893224-B2 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7723512-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090318676-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090312531-A1 | OLIGNUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-7632932-B2 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20090281299-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| US-4169936-A | CROWN ETHER AND N-ACYL PYRROLIDONE ACTIVATED COPOLYMERIZATION OF 2-PYRROLIDONE AND CAPROLACTAM | CHEVRON RESEARCH COMPANY (US) | 1979-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281299-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | DUT, PNP, RNGTT | LMNA 3051/4885SMN1; SMN2 3084/4885CRHBP 1247/4885 |
| US-20090312531-A1 | OLIGNUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | DUT, NOP58, DPYD | LMNA 3066/4885SMN1; SMN2 1454/4885CRHBP 1433/4885 |
| US-20120107272-A1 | SYNTHETIC METHODS AND DERIVATIVES OF TRIPHOSPHATE OLIGONUCLEOTIDES | IFNAR1, DDX18, STING1 | LMNA 4707/4885SMN1; SMN2 2257/4885CRHBP 3752/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | LMNA 2525/4885SMN1; SMN2 2311/4885CRHBP 709/4885 |
| US-20090318676-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | DUT, PNP, RNGTT | LMNA 3051/4885SMN1; SMN2 3084/4885CRHBP 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.